Click below to view presentation
Myeloma NZ
Ken Romeril speech at the Burden of Disease launch 26 June, 2019
Welcome and introduction of Dr Liz Craig. No mai, haere mai: Dr Craig, Members of Parliament, colleagues, health sector professionals, patients and...
Dr. Nadeem on Individualizing Therapy in Multiple Myeloma
Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses individualizing...
The VCAT study
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous...
Lenalidomide-related Progressive Multifocal Leukoencephalopathy: A Case Report and Review of Drug-related Cases in Multiple Myeloma
Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the central nervous system caused by reactivation of John...
Improved Clinical Outcomes in Relapsed/Refractory Multiple Myeloma With Daratumumab Re-Treatment
This story was originally published on the Hematology Advisor The introduction of monoclonal antibodies and immunomodulators into earlier lines of...
New medicine for multiple myeloma shows promising results
A new drug reduced the risk of relapse and increased survival by five months, according to a recent study. The results were presented at a cancer...
New Zealand falling behind rest of world in cancer treatment, according to new myeloma report
Originally published on Health Industry Hub The management of New Zealand’s most common blood cancer, myeloma, is falling behind the rest of the...
New Zealand lacks treatment access to myeloma patients – Myeloma New Zealand
This story was originally published on RNZ An advocate group is warning that New Zealanders are dying from a common blood cancer because they've...
NZ falling behind rest of world in cancer treatment – Myeloma NZ
The management of New Zealand’s most common blood cancer, myeloma, is falling behind the rest of the world, putting lives at unnecessary risk of...
New Zealand lacking best treatment options for blood cancer patients, warns Myeloma NZ
This story was originally published on the NZ Herald Kiwis diagnosed with the country's most common form of blood cancer are being put at...
Innovation Fuels Survival Gains in Multiple Myeloma
In the past 20 years, we’ve been very fortunate in the development of effective myeloma therapies and have seen remarkable progress for our...